CIRIUM
5.10.2022 09:01:49 CEST | Business Wire | Press release
Vueling, an airline which forms part of IAG (International Airlines Group), has signed a landmark deal with Cirium, the aviation analytics company, to improve airline operational efficiencies through the Cirium Sky managed data warehouse and analytics solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005079/en/
Vueling and Cirium sign a deal for Cirium Sky, to dramatically improve airline operational performance (Photo: Business Wire)
The multi-year deal provides Vueling, with access to Cirium’s new data aviation warehouse and analytics capability.
This partnership will allow the airline to gain a unique insight from over 25 operational factors, and ultimately provide a best-in-traveller experience.
Cirium Sky will enable more effective flight planning, especially around disruption, to minimize delays for its customers.
Jeremy Bowen, Cirium CEO, said: “Our aviation data warehouse, Cirium Sky, is critical in supporting Vueling’s digital transformation initiatives and will enable the airline to improve flight operations, reduce travel delays and set the stage for operational excellence.”
Vueling is viewed by Cirium as the agile and innovative leader in IAG thanks to the implementation of several initiatives, including Vueling Transform, to unlock its full potential through digitization and low-cost leadership.
Oliver Iffert, Vueling Chief Operations Officer , said: “Coming out of the pandemic, Vueling is emerging even more efficient and competitive as we prioritize actionable insights backed by a wealth of data and context.”
“Data is key to assessing our operations and identifying ways to provide a passenger experience that stands out.”
“Using Cirium Sky, Vueling can plan flights more effectively and analyze flight delays based on accurate data. We will, as a result, drive a reduction in delays and minimize disruptions.”
The move to Cirium Sky transitions Vueling from using multiple data providers and data held in siloed systems to a single source of aviation data and analytics.
This strategic data and analytics partnership provides the airline with access to the industry’s largest data warehouse, which has a 360-degree view of flights, as well as prescriptive and predictive analytics to anticipate future operational challenges.
Added Bowen: “Improving operations is not only key for the traveller experience but also for tackling the liquidity issues and capacity recovery that airlines are facing in the wake of COVID-19.“
“By democratizing data and enabling smarter and faster decision making, airlines would see huge savings. We are delighted to partner with Vueling and drive value for their business.”
Cirium Sky is purpose-built to enable airlines, airports, financial institutions, aircraft manufacturers, and travel distributors to unlock the value in aviation data.
Find out more about Cirium Sky.
Ends
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com
About Vueling
Vueling, a company which forms part of IAG, is key in connectivity in Spain, the largest domestic market in Europe. For this winter 2022, the company has a network of more than 240 short and medium-haul routes in Europe, North Africa and the Middle East, which are operated with a fleet of Airbus A319, A320, A320neo and A321 models. In 2021, Vueling has won the World Airline Awards as the "Best Low Cost Airline in Europe".
As part of IAG, Vueling shares the vision of leading the field of sustainability within the global airline industry. That is why the company develops all its actions within the framework of the "Flightpath Net Zero" program, through which the goal of achieving net zero CO2 emissions in 2050 has been established.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005079/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom